ProtoKinetix, Inc.
DALTON, OH · CIK 0001128189 · Biotech · Public
AAGP®, a patented molecule for enhancing cell survival
protokinetix.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $3.8M
- 34 Form D · Oct 2025
- 12 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 9
- 3 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $125,000 | |
| Private capital raised | Form D · SEC | $250,000 | |
| Private capital raised | Form D · SEC | $50,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $25,000 | |
| Private capital raised | Form D · SEC | $92,500 | |
| Private capital raised | Form D · SEC | $125,000 | |
| Private capital raised | Form D · SEC | $160,000 | |
| Private capital raised | Form D · SEC | $166,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $260,000 | |
| Private capital raised | Form D · SEC | $80,000 | |
| Private capital raised | Form D · SEC | $220,000 | |
| Private capital raised | Form D · SEC | $110,000 | |
| Private capital raised | Form D · SEC | $200,000 | |
| Private capital raised | Form D · SEC | $272,000 | |
| Private capital raised | Form D · SEC | $130,000 | |
| Private capital raised | Form D · SEC | $74,000 | |
| Private capital raised | Form D · SEC | $25,000 | |
| Private capital raised | Form D · SEC | $86,200 | |
| Private capital raised | Form D · SEC | $43,500 | |
| Private capital raised | Form D · SEC | $204,880 | |
| Private capital raised | Form D · SEC | $24,000 | |
| Private capital raised | Form D · SEC | $60,000 | |
| Private capital raised | Form D · SEC | $20,000 | |
| Private capital raised | Form D · SEC | $135,000 | |
| Private capital raised | Form D · SEC | $215,000 | |
| Private capital raised | Form D · SEC | $80,000 | |
| Private capital raised | Form D · SEC | $73,000 | |
| Private capital raised | Form D · SEC | $109,000 | |
| Private capital raised | Form D · SEC | $110,000 | |
| Private capital raised | Form D · SEC | $35,000 | |
| Private capital raised | Form D · SEC | $57,000 | |
| Private capital raised | Form D · SEC | $5,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2314 | HALO BIOSCIENCES, INC. | — | — |
| 2315 | Bond Biosciences, Inc. | — | $18M |
| 2316 | Moleculin Biotech, Inc. | — | $6.0M |
| 2317 | ProtoKinetix, Inc. | — | $3.8M |
| 2318 | CERO THERAPEUTICS HOLDINGS, INC. | — | $16M |
| 2319 | INMUNE BIO, INC. | — | $8.0M |
| 2320 | ARUKA BIO, INC. | — | $3.6M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael GuzzettaDirector · Executive Officer
- Peter JensenDirector
- Edward McDonoughDirector
- Clarence SmithDirector · Executive Officer
- Susan WoodwardExecutive Officer
Patents
- Use Of Anti-aging Glycopeptides To Enhance Pancreatic Cell Health, Survival And Improve Transplant Outcomeapplication
- Use Of Anti-aging Glycopeptides To Enhance Pancreatic Cell Health, Survival And Improve Transplant Outcomegranted
- Use Of Anti-aging Glycoprotein For Enhancing Survival Of Neurosensory Precursor Cellsgranted
- Use Of Anti-aging Glycopeptides For Treatment Of Dry Eye Disease, Retinal Degenerative Diseases, Or Occular Inflammationapplication
- Use Of Anti-aging Glycopeptides For Inhibition Of Immune Rejection Of A Graftapplication
- Use Of Anti-aging Glycoprotein For Enhancing Survival Of Neurosensory Precursor Cellsgranted
- Use Of Anti-aging Glycopeptides To Enhance Beta Cell Health, Survival And Improve Transplant Outcomeapplication
- Use Of Anti-aging Glycopeptides To Enhance Pancreatic Cell Health Survival And Improve Transplant Outcomeapplication
- Use Of Anti-aging Glycopeptides To Enhance Pancreatic Cell Health, Survival And Improve Transplant Outcomeapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.